The emergence of innovative ideas and projects is one of the positive aspects of the COVID-19 pandemic. More precisely, it became apparent just how important it is to focus on the development of pharmaceuticals, not only to continue to fight existing diseases but also to prevent future outbreaks as the likelihood of pandemics could increase threefold in the upcoming years.

However, while focusing on its importance, we must also acknowledge the ambivalent narrative that characterises the industry. We need to address the continuous distrust that has built up in pharma throughout the years and acknowledge its impact on investors’ trust and participation. By addressing those setbacks, the chances of building a strong pathway for the acceleration of drug technologies increase.

With the global pharmaceutical industry continuing to grow, the industry offers a wide range of opportunities for employment in the research, development, production, and distribution of drugs which, consequently, results in more growth. Therefore, not only is the pharmaceutical industry beneficial for society as a whole, but its growth also means an increase in jobs as this industry is, directly and indirectly, sustaining approximately 4.7 million jobs in the United States.

Profitable and innovative industry

The importance of the pharma industry for humankind makes it an attractive asset for long-term investors. After all, the whole purpose of this industry is to help humankind live longer, better, and healthier lives. In fact, not only was the gross margin of the global pharmaceutical industry measured at 88.13% in Q4 of 2022 but it is also expected to reach over US$ 353 billion in market size by 2030 thereby showing that the industry is generating and will continue to generate cash flow for investors.

So, even amid a period of slow growth, a recession will not necessarily result in making a loss - unless investments are sold at a loss. That being said, it is noteworthy that the US faced 12 recessions in the 20th century. A prolonged drop in investment prices will generally not last as long as the bull market, meaning that even though the industry is marked by the ongoing economic struggle, it will most likely recover and so will your investments.

Investing in pharma will grant the innovations that humankind needs, such as the enhancement of the patient-centric approach, personalised medicine, and analytical techniques. Simultaneously, it will continue to spur economic growth and stimulate economic competition, all, consequently, generating reciprocal growth.